Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

The mPIVAS study: efficacy of PSYLOG application in monitoring of antipsychotics side-effects (CROSBI ID 684136)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Bošnjak Kuharić, Dina ; Makarić, Porin ; Silić, Ante ; Ostojić, Draženka ; Čulo, Ilaria ; Savić, Aleksandar ; Đuran, Nataša ; Bajić, Žarko ; Ćelić Ružić, Mirela ; Petric, Danijela et al. The mPIVAS study: efficacy of PSYLOG application in monitoring of antipsychotics side-effects. 2019. str. WCP19-0133-WCP19-0133

Podaci o odgovornosti

Bošnjak Kuharić, Dina ; Makarić, Porin ; Silić, Ante ; Ostojić, Draženka ; Čulo, Ilaria ; Savić, Aleksandar ; Đuran, Nataša ; Bajić, Žarko ; Ćelić Ružić, Mirela ; Petric, Danijela ; Rojnić Kuzman, Martina

engleski

The mPIVAS study: efficacy of PSYLOG application in monitoring of antipsychotics side-effects

Objectives: The mPIVAS study is designed to assess efficacy of Android smart-phone application PsyLOG in monitoring and controlling side-effects of antipsychotics (SEA). Background and aims: Monitoring of SEA is often subjective, depending on ad-hoc reporting from patients (and their care- givers) and frequently leads to prolonged duration of SEA and possible therapy discontinuation. We constructed this randomized control trial aiming to test the use of mobile technology in improvement of monitoring of SEA. Materials and methods: Patients diagnosed with schizophrenia spectrum disorder treated with antipsychotics for up to five years will be recruited from five Croatian psychiatric hospitals and randomized to three groups differentiated by SEA monitoring method: PsyLOG application, GASS questionnaire and standard monitoring. Additional assessment will include questionnaires for therapeutic alliance and quality of life. During the three-month follow-up period, participants will be assessed after one and after three months from baseline. Results: We plan to recruit 65 patients per group (80% power with expected ≤15% of drop out and missing data). We plan to analyze the differences between three groups in the proportion of patients whose antipsychotic treatment was modified in any way due to side effects and the median time for it, changes in therapeutic alliance and patients’ quality of life. Conclusions: Identifying effective measures for monitoring of SEA could contribute to patients’ health, quality of life and adherence by improving their knowledge about pharmacotherapy, recognition of side-effects and involvement in their treatment, as well as to help clinicians in choosing more appropriate medications.

mPIVAS ; mobile application ; side-effects ; antipsychotics ; first-episode psychosis

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

WCP19-0133-WCP19-0133.

2019.

objavljeno

Podaci o matičnoj publikaciji

Podaci o skupu

19th WPA World Congress of Psychiatry

poster

21.08.2019-24.08.2019

Lisabon, Portugal

Povezanost rada

Kliničke medicinske znanosti